MOC2 Syngeneic Model Overview
The MOC2 syngeneic model is a murine head and neck squamous cell carcinoma (HNSCC) system derived from C57BL/6 mice. It represents a poorly immunogenic and highly aggressive variant within the Murine Oral Carcinoma (MOC) series and is widely employed in preclinical studies of tumor immune evasion, metastasis, and therapeutic resistance. Developed through 4-nitroquinoline-1-oxide (4NQO)–induced carcinogenesis, MOC2 recapitulates the invasive, poorly differentiated histology and immunosuppressive tumor microenvironment characteristic of advanced human HNSCC.
When implanted subcutaneously or orthotopically (e.g., in the oral cavity or tongue), MOC2 cells form rapidly growing, locally invasive tumors with limited responsiveness to immune checkpoint inhibitors. The model’s robust growth kinetics, immune-excluded phenotype, and reproducible aggressiveness make it a critical system for testing combination immunotherapy, macrophage reprogramming strategies, and T-cell infiltration enhancement approaches.
Request a Custom Quote for MOC2 Syngeneic ModelBiological and Molecular Characteristics
The MOC2 cell line was derived alongside MOC1 from oral tumors induced by 4NQO in C57BL/6 mice, but it displays markedly different biological behavior. Unlike MOC1, which is moderately immunogenic and well differentiated, MOC2 is poorly differentiated, fast growing, and immune resistant. The cells exhibit spindle-shaped morphology, reduced E-cadherin expression, and strong vimentin positivity, reflecting a mesenchymal, invasive phenotype.
Molecular profiling demonstrates activation of EGFR, PI3K-AKT, and STAT3 signaling pathways, contributing to uncontrolled proliferation, angiogenesis, and resistance to apoptosis. The tumor microenvironment is highly immunosuppressive, with abundant myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and regulatory T cells (Tregs). These features collectively reproduce the immune-excluded and therapy-resistant characteristics of aggressive human head and neck carcinomas.
| Parameter | Description |
|---|---|
| Host strain | C57BL/6 (female, 6–8 weeks) |
| Tumor origin | Chemically induced oral squamous cell carcinoma (mouse) |
| Histological type | Poorly differentiated squamous cell carcinoma |
| Inoculation route | Subcutaneous or orthotopic (oral cavity or tongue) |
| Tumor take rate | >95% |
| Doubling time | Approximately 3–4 days in vivo |
| Metastatic potential | Moderate to high; regional spread possible |
| Immunophenotype | Vimentin⁺, PD-L1⁺, reduced E-cadherin, EGFR⁺ |
| Common applications | Immunotherapy resistance, macrophage modulation, radiotherapy, T-cell infiltration studies |
In Vivo Model Development and Tumorigenicity
The MOC2 model can be established by subcutaneous or orthotopic implantation of tumor cells into immunocompetent C57BL/6 mice. Subcutaneous tumors form rapidly and allow for straightforward monitoring of tumor kinetics, while orthotopic implantation into the tongue or buccal mucosa recapitulates the invasive and desmoplastic characteristics of advanced HNSCC. Tumors typically appear within 5–7 days after inoculation, demonstrating aggressive local expansion and stromal remodeling.
Because of its poor immunogenicity, MOC2 is frequently employed in studies that aim to convert immune-cold tumors into immune-active phenotypes. This model supports investigation of immune checkpoint blockade resistance, macrophage depletion and reprogramming, and radiation-induced immune activation. Its reproducible tumor formation and rapid progression make it a highly practical system for evaluating immunomodulatory therapies in refractory cancer settings.
Request a Custom Quote for MOC2 Syngeneic ModelHistopathology and Immunohistochemical Profile
Histopathological analysis of MOC2 tumors reveals poorly differentiated squamous carcinoma composed of pleomorphic cells with hyperchromatic nuclei, minimal keratinization, and high mitotic activity. Tumors exhibit extensive stromal desmoplasia, vascularization, and invasion into surrounding soft tissue. The microenvironment is densely populated by macrophages and myeloid cells, with limited T-cell infiltration, reflecting immune exclusion.
Immunohistochemical staining demonstrates loss of E-cadherin and strong vimentin expression, indicative of epithelial–mesenchymal transition (EMT). Ki-67 labeling reveals high proliferative activity, while PD-L1 expression is moderate to strong and inducible under interferon stimulation. CD3 and CD8 staining identify sparse T-cell presence, whereas F4/80 and CD11b highlight dense macrophage and MDSC infiltration. These features align closely with the aggressive and immune-suppressive pathology of advanced human HNSCC.
Preclinical Applications and Drug Response
The MOC2 syngeneic model is a benchmark for studying immune resistance and therapeutic modulation in head and neck cancer. It exhibits minimal response to monotherapy with PD-1 or CTLA-4 inhibitors, reflecting a cold immune microenvironment. However, combination treatments integrating radiation, cytokine agonists, or macrophage-targeting agents have demonstrated enhanced immune infiltration and tumor regression.
MOC2 is also widely used to evaluate radiotherapy–immunotherapy synergy, stromal remodeling, and metabolic interventions aimed at overcoming immune exclusion. The model’s aggressive growth and immune-suppressive profile make it an ideal choice for testing strategies that induce T-cell trafficking, reprogram macrophages, or enhance antigen presentation. Due to its biological fidelity to treatment-refractory HNSCC, MOC2 remains one of the most clinically relevant syngeneic systems for advanced immuno-oncology research.
Request This Model
To request the MOC2 syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for MOC2 Syngeneic Model